BioHarvest Sciences, Inc. · NASDAQ:BHST
BioHarvest Sciences — Investor Presentation (August 2026)
22 slides from BioHarvest Sciences's investor presentation, August 2026
Slide 1: The Industrial Plant Cell Culture Company
Investor Corporate Presentation | August 2026 The Industrial Plant Cell Culture Company NASDAQ: BHST
Slide 2: Forward Looking Statements
Forward Looking Statements Cautionary Note Regarding Forward-Looking Statements This presentation contains "forward-looking statements." The statements contained in this presentation that are not purely historical are forward-looking statements. Forward-looking statements give the Company's current
Slide 3: Leadership Team
BIOHARVEST SCIENCES Leadership Team DR. YOCHI HAGAY BAR DICHTER Co-Founder & Chief Technology Officer Chief Financial Officer 20+ years experience in the 8+ years experience leading pharmaceutical & biotech space BioHarvest finance team DR. ILANA BELZER ILAN SOBEL Chief Operating Officer Co-Founder,
Slide 4: BioHarvest At-a-Glance
BIOHARVEST SCIENCES BioHarvest At-a-Glance We are the global leader in plant cell biology We are able to scale plant cell cultures rapidly AND precisely. Our proprietary platform allows us to do this from the blueprint of just one plant, preventing us from needing the footprint or capital to grow ma
Slide 5: Investment Summary
BIOHARVEST SCIENCES Investment Summary Optimized Business Model Industrial Manufacturing Infrastructure Two sources of value-creation; D2C provides $5M CapEx historical facility ROI reference; certainty immediate growth support of supply chain unencumbered with stops and starts Platform Optionality:
Slide 6: Natural-Based Molecules: A Fast-Growing Market Opportunity
Natural-Based Molecules: BIOHARVEST SCIENCES A Fast-Growing Market Opportunity Natural Pharma / Biotech Nutraceutical Efficacious North Star of BHST To Proprietary Discover, Develop, Plant-Based Manufacture & Democratize NON – GMO Life-Changing Compounds Molecules From Plants That Change The World O
Slide 7: Nature is NOT an Industrial Supply Chain
Supply risk BIOHARVEST SCIENCES Nature is NOT an Industrial Supply Scarcity Inconsistency Chain Controlled Industrial Biology The bottleneck is not demand, it is reliable supply Purity Climate / land 7
Slide 8: Industrial Biology Platform for Plant-Derived Innovation
BIOHARVEST SCIENCES BIOHARVEST SCIENCES Industrial Biology Industrial Platform Biology forfor Platform Plant-Derived Innovation Plant-Derived Innovation Programmable Plant Biology Nature’s most valuable molecules Precision Botanics Controlled Cell Banks A category-defining technology platform with p
Slide 9: Botanical Synthesis
BIOHARVEST SCIENCES Botanical Synthesis Programmable plant cell biology generating precision botanics Performed Once The Plant Cell Isolation and Cell bank Potency Magnification Perpetual Process Small Scale Large Scale Cell bank Propagation Propagation Drying Final Molecule UPSTREAM DOWNSTREAM From
Slide 10: Technology Benefits
BIOHARVEST SCIENCES Technology Benefits Scalable, predictable and sustainable Superior bioavailability one plant yields supply chain certainty beyond natural and unlimited production limitations Lower COGs Controlled consistency, compared to extraction purity, and non-GMO reproducibility Ultra-poten
Slide 11: AI Driven-Development
BIOHARVEST SCIENCES AI Driven-Development Predictive models reduce scale-up and error Computer vision monitors cell culture in real time Multi-sensor data fusion optimizes yield and consistency In-silico library matches molecules to target use-cases AI-supported discovery expands the CDMO pipeline A
Slide 12: Product Development Pipeline
BIOHARVEST SCIENCES Product Development Pipeline High-value Proprietary Assets Create Multiple Pathways For Future Revenue Generation Through Strategic Partnerships, Commercialization, & Licensing Opportunities Piceid Resveratrol Verbascocide PGG Polyphenol Complex Aromatic Complex Protein Molecule
Slide 13: Program Pipeline Commercial and Development Programs
BIOHARVEST SCIENCES Program Pipeline Commercial and Development Programs STAGE 1 STAGE 2 STAGE 3 INDUSTRIAL & [$.5-$1M] [~$1M] [~1M] COMMERCIAL VIABILITY Over $100 Million in Revenues Olive Cell Final Molecule Compound Ready for Production Fragrance CDMO Client Q2 2026 – Stage 2 contract, Completed
Slide 14: D2C Business Shows The Power Of Our Proprietary Compounds
D2C Business Shows The Power Of Our Proprietary Compounds & Ability To Manufacture At Scale M AR KE T L E ADE R · U. S . A. INTRODUCING THE #1 BLOOD FLOW Backed by 17 Years of Science and Innovation. RESVERATROL BRAND IN THE U.S. Clinically proven to increase arterial dilation. * #1 Blood Flow Resve
Slide 15: The Two-Lens View: D2C Products and CDMO Platform
BIOHARVEST SCIENCES The Two-Lens View One Company viewed through two complimentary value creation engines D2C PRODUCTS CDMO PLATFORM VINIA commercial franchise Strategic partner for plant-derived innovation 2026 guidance: $33-$35M 2026 guidance: $4–5M Subscription-driven D2C model Development revenu
Slide 16: BioHarvest Secures 20 Ton Manufacturing & Supply Agreement
THE CDMO BioHarvest Secures 20 Ton Manufacturing & Supply Agreement for Rare Botanical Luxury Fragrance. Estimated $20-$30M Revenue in 2027-2028 SESQUITERPENES CHROMONES 16
Slide 17: Unlocking Multiple Opportunities To Take A Leadership Position
THE CDMO Unlocking Multiple Opportunities to Take a Leadership Position in the Production of Rare Fragrances using Similar Chemistry Developed Future molecules based on the same intellectual property BioHarvest has developed for the growth of sesquiterpenes, chromones and apocarotenoids. MAT ERIAL Y
Slide 18: CDMO Engine For Growth Across Major Industries
BIOHARVEST SCIENCES CDMO Engine For Growth Across 4 Major Industries COSMETICS/FRAGRANCES NUTRACEUTICALS STATUS STATUS Completed Stage 1 Completed Stage 1 Now in Stage 2 with 20 Ton Now in Stage 2 Manufacturing Deal Signed MULTI- BILLION $ OPPORTUNITY PHARMA & BIOTECH NUTRITION & SWEETENERS STATUS S
Slide 19: CDMO Revenue Engine
THE CDMO CDMO Revenue Engine More simultaneous projects create more chances to reach manufacturing and royalties Development Manufacturing Royalty / revenue revenue ownership upside Paid stages de-risk Commercial supply at scale Participation in successful projects and create near- can become recurr
Slide 20: The Inflection Point: From Validation To Acceleration
BIOHARVEST SCIENCES BIOHARVEST SCIENCES The TheInflection InflectionPoint Point: From Validation : From toto Validation Acceleration Acceleration 1 → 2 → 3 → 4 → D2C CDMO Manufacturing AI + scale proof base data VINIA has become a Four third-party The same infrastructure Years of process data meanin
Slide 21: Integrated Industrial Infrastructure
BIOHARVEST SCIENCES Integrated Industrial Infrastructure R&D, scale-up and production under one operating platform 20–25 tons 75+ tons current annual expansion production capacity path $5M capex Israel low cost of capital deep biotech and vs revenue process expertise base generated Our platform scal
Slide 22: Financial Snapshot
BIOHARVEST SCIENCES Financial Snapshot CDMO revenue ($M) Consolidated D2C revenue ($M) *Includes internal Vinia transfers revenue ($M) 37-40 33-35 32.6 34.5 25.2 25.2 12-14 9.1 0 2024 2025 2026E 2024 2025 2026E 2024 2025 2026E 22
BioHarvest Sciences — Investor Presentation (August 2026) on 6ix